SC-26196

SC-26196 has been used as an inhibitor of delta6 (6) fatty acid desaturase:

• in mouse inner medullary collecting duct (IMCD3) and human (female) embryonic kidney (HEK) 293 cell culture as Dulbeccos modified eagles medium (DMEM) component
• in hepatic HepG2 cells
• in glioblastoma cell lines to test its effect post-radiation treatments

Packaging
5, 25 mg in glass bottle
Biochem/physiol Actions
SC-26196 is a Delta6 fatty acid desaturase (Delta6D) inhibitor. It specifically inhibited Delta6D activity with an IC(50) value of 100 nM. The rate-limiting step in arachidonic acid synthesis is the desaturation of dietary linoleic acid by Delta6D. SC-26196 completely prevented this conversion of linoleic acid to arachidonic acid.
Features and Benefits
This compound is also offered as part of Sigmas Library of Pharmacologically Active Compounds (LOPAC®Pfizer), a collection of 90 Pfizer-developed drugs and research tools. Click here, to learn more.
This compound was developed by Pfizer for Lipid Signaling research,. To learn more about Sigmas partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer,.
To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here,.
Sold for research purposes under agreement from Pfizer Inc.
LOPAC is a registered trademark of Sigma-Aldrich Co. LLC
Pfizer is a registered trademark of Pfizer, Inc.